Management of myelodysplastic syndromes after failure of response to hypomethylating agents

by Angela Gil-Perez, Guillermo Montalban-Bravo
Published 2019-05-01

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

by Abhishek Maiti, Courtney D. DiNardo, Naval G. Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Sanam Loghavi, Kathryn S. Montalbano, Sherry Pierce, William G. Wierda, Hagop M. Kantarjian, Marina Y. Konopleva
Published 2021-02-01

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

by Sarah A. Bannon, Mark J. Routbort, Guillermo Montalban-Bravo, Rohtesh S. Mehta, Fatima Zahra Jelloul, Koichi Takahashi, Naval Daver, Betul Oran, Naveen Pemmaraju, Gautam Borthakur, Kiran Naqvi, Ghayas Issa, Koji Sasaki, Yesid Alvarado, Tapan M. Kadia, Marina Konopleva, Rashmi Kanagal Shamanna, Joseph D. Khoury, Farhad Ravandi, Richard Champlin, Hagop M. Kantarjian, Kapil Bhalla, Guillermo Garcia-Manero, Keyur P. Patel, Courtney D. DiNardo
Published 2021-01-01

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

by Warren Fiskus, Christopher P. Mill, Behnam Nabet, Dimuthu Perera, Christine Birdwell, Taghi Manshouri, Bernardo Lara, Tapan M. Kadia, Courtney DiNardo, Koichi Takahashi, Naval Daver, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Steven Kornblau, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia Manero, Sunil Sharma, Matthew Stubbs, Xiaoping Su, Michael R. Green, Cristian Coarfa, Srdan Verstovsek, Joseph D. Khoury, Christopher R. Vakoc, Kapil N. Bhalla
Published 2021-05-01

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

by Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Published 2021-02-01

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

by Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Published 2020-10-01

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

by Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour, David Sallman, Anthony Michael Hunter, Christopher Benton, Kelly S. Chien, Rajyalakshmi Luthra, Carlos E. Bueso-Ramos, Tapan Kadia, Michael Andreeff, Rami S. Komrokji, Najla H Al Ali, Nicholas Short, Naval Daver, Mark J. Routbort, Joseph D. Khoury, Keyur Patel, Irene Ganan-Gomez, Yue Wei, Gautam Borthakur, Farhad Ravandi, Kim-Anh Do, Kelly A. Soltysiak, Olivier Lichtarge, L. Jeffrey Medeiros, Hagop Kantarjian, Guillermo Garcia-Manero
Published 2021-03-01